- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Marksans Pharma Limited — Important, 26-06-2026: Updates
26-06-2026 | 02:35 pm
26-06-2026 | 02:35 pm
Marksans Pharma reports full-year consolidated revenue up 12.5% to ₹2,950.94 Cr, with PAT rising 9.8% to ₹420.06 Cr. EPS grew to ₹9.22. The company established new wholly-owned subsidiaries in Ireland and Canada, granted 400,000 employee stock options, and declared a final dividend of ₹0.90 per share.
No comments yet. Be the first to comment!